{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116307","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.418808+00:00","generated_at":"2026-06-08T06:07:05.088289+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytoSorbents Q3 product sales up 20% to $7.8M, gross margin improves to 72%, STAR-T data expected year-end","bullets":["Q3 product sales $7.8M (+20% YoY); total revenue $8.8M (+9% YoY).","Product gross margin 72% vs 55% a year ago, driven by manufacturing efficiencies.","Pivotal STAR-T trial database lock nearing; initial data analysis expected before year-end.","Cash and restricted cash $10.0M; company exploring alternative financing after terminating equity offering.","Over 221,000 CytoSorb devices delivered cumulatively; expansion in Brazil approved for shock treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116307","json":"https://secwatch.observer/filing/0001104659-23-116307.json","markdown":"https://secwatch.observer/filing/0001104659-23-116307.md","text":"https://secwatch.observer/filing/0001104659-23-116307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923116307/0001104659-23-116307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923116307/tm2330311d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:07:05.088289+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"132fefa34feafa2291a02abaa79c8e57ef13f9cb","claim":"Cytosorbents Corp reported the quarter ended September 30, 2023 results: revenue Total revenue for Q3 2023, including product sales and grant income, was $8.8 million.","evidence_excerpt":"On November 9, 2023, CytoSorbents Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923116307/0001104659-23-116307-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"Total revenue for Q3 2023, including product sales and grant income, was $8.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}